IMMUNOGLOBULIN G1 (HUMAN-RAT MONOCLONAL CAMPATH-1H .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD52), DISULFIDE WITH HUMAN-RAT MONOCLONAL CAMPATH-1H LIGHT CHAIN, DIMER
DiGeorge Syndrome
Paul Szabolcsmonoclonal_antibodyPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 89/ 100
Competitive context
3 Active assets in the DiGeorge Syndrome cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Evomela Paul Szabolcs | Phase 2 | CCC |
Fludarabine Paul Szabolcs | Phase 2 | CCC |
Thiotepa Washington University School of Medicine | Phase 2 | CCC |
DACLIZUMAB Sumitomo Pharma Switzerland GmbH | Phase 1/2 | CCC |
Rabbit Anti-Thymocyte Globulin Sumitomo Pharma Switzerland GmbH | Phase 1/2 | CCC |
CHLOROPTIC-P S.O.P. COMPONENT PREDNISOLONE Sumitomo Pharma Switzerland GmbH | Phase 1/2 | CCC |
TACROLIMUS Sumitomo Pharma Switzerland GmbH | Phase 1/2 | CCC |
CYCLOSPORIN A Sumitomo Pharma Switzerland GmbH | Phase 1/2 | CCC |
Same molecule, other indications
IMMUNOGLOBULIN G1 (HUMAN-RAT MONOCLONAL CAMPATH-1H .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD52), DISULFIDE WITH HUMAN-RAT MONOCLONAL CAMPATH-1H LIGHT CHAIN, DIMER is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →